

June 23, 2023



# Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting

NEW YORK, June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago, June 24-27, 2023. These abstracts exhibit the breadth of Actinium's technological and clinical endeavors over the past year that are now culminating in targeted radiotherapies that meaningfully improve the outcomes of cancer patients.



## Details of the SNMMI oral presentations:

*Presentation Title:* Machine learning applications to optimize dosimetric imaging of I131-apamistamab for bone marrow conditioning in relapsed/refractory acute myeloid leukemia (R/R AML)

*Session:* New Developments in Radiopharmaceutical Therapy

*Date and Time:* June 25, 5:00pm – 6:15pm CT

*Presentation Title:* Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial

*Session:* Hematologic Malignancies

*Date and Time:* June 26, 12:45 PM – 2:00 PM CT

*Presentation Title:* Administration and radiation safety of high-dose Iomab-B (I131-apamistamab) demonstrated in multiple clinical settings: Experience from the large multicenter phase 3 SIERRA trial for targeted conditioning of patients with relapsed/refractory AML

*Session:* Hematologic Malignancies

*Date and Time:* June 26, 12:45 PM – 2:00 PM CT

## Details of the SNMMI poster presentations:

All posters will be accessible for viewing for the entirety of the conference. The general session is Science Pavilion – Meet the Authors Session: June 26, 5:15pm – 6:15pm CT

*Abstract Title:* Organ-specific dosimetry to estimate potential toxicity thresholds of Actimab-A (lintuzumab-Ac225) used in combination with venetoclax in relapsed/refractory AML

*Track:* Molecular Targeting Probes

*Date and Time:* June 25, 6:30 – 8:30 pm CT

*Abstract Title:* Relative biological effectiveness of antibody radioconjugates (ARCs): In vitro dosimetric evaluation to streamline pre-clinical decision-making

*Track:* Oncology, Basic and Translational

*Date and Time:* June 27, 12:30 – 2:00 pm CT

*Abstract Title:* Streamlining personalized dosimetry for I131-apamistamab using a Co-57 sheet source to circumvent the need for radionuclide-specific attenuation correction

*Track:* Molecular Targeting Probes-Radioactive & Nonradioactive

*Date and Time:* June 27, 12:30 – 2:00 pm CT

## **About Actinium**

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.

For more information, please visit: <https://www.actiniumpharma.com/>

## **Forward-Looking Statements**

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to

time.

**Contact:**

Matthew Beck  
Vice President Investor Relations & Communications  
[mbeck@actiniumpharma.com](mailto:mbeck@actiniumpharma.com)  
(917) 415-1750

View original content to download multimedia <https://www.prnewswire.com/news-releases/actinium-pharma-highlights-six-abstracts-accepted-for-oral-and-poster-presentation-at-the-snmmi-2023-annual-meeting-301860749.html>

SOURCE Actinium Pharmaceuticals, Inc.